IMCR - Immunocore's eye cancer drug Kimmtrak sees preliminary net sales of $140M in FY22
- Immunocore ( NASDAQ: IMCR ) reported preliminary total net product and net pre-product revenue (net sales) of eye cancer drug Kimmtrak (tebentafusp-tebn) and tebentafusp of about $50M in Q4, rising +25% Q/Q.
- For full year 2022, preliminary total net sales for Kimmtrak and tebentafusp were ~$140M, according to the company.
- Preliminary cash and cash equivalents were ~$400M at year end 2022.
- Immunocore said, in 2023, it will continue to launch in additional countries and establish Kimmtrak globally as first line treatment for metastatic uveal melanoma, while exploring how to enhance patient convenience. In addition, the company is enrolling patients in a phase 2/3 trial to evlaute the potential of tebentafusp in advanced cutaneous melanoma.
For further details see:
Immunocore's eye cancer drug Kimmtrak sees preliminary net sales of $140M in FY22